AbbVie’s latest deal signals that Big Pharma’s appetite for next‑gen immunology assets is not just alive, it is visibly bulking up for the long haul, and investors who ignore this corner of the market may find themselves benched just as the real…
Sanofi’s latest Dupixent win and Eupraxia Pharmaceuticals’ quiet grind in eosinophilic esophagitis (“EoE”) still tell a coherent, investor‑friendly story: the type 2 inflammation boom is alive, and there is room on the highway for both mega‑cap platforms and focused innovators. For investors,…
US stocks finished higher Thursday as Wall Street digested a record-shattering SpaceX IPO, resilient macro data, and the global spotlight of the 2026 FIFA World Cup opening ceremonies.
Market recap: risk-on into mega-IPO
Major U.S. equity benchmarks advanced, with broad-based gains across…
U.S. stocks rebounded Monday, June 8, 2026, led by a sharp recovery in semiconductor and other AI‑linked names after last week’s tech rout, even as investors digested hotter labor data, higher yields, and renewed Middle East tensions.
Market wrap: risk back on,…
U.S. equities finished the week ending June 5, 2026 under pressure, as a hotter‑than‑expected jobs print pushed Treasury yields higher, revived “higher for longer” Fed fears, and triggered profit‑taking in the year’s AI and semiconductor winners, even as select earnings stories like…
U.S. stocks advanced on Thursday, June 4, 2026, as investors bought the dip in cyclicals and quality tech while a pullback in oil prices eased some inflation anxiety ahead of Friday’s jobs report. The Dow pushed back toward record territory even as…
U.S. stocks pulled back on Wednesday, June 3, 2026, as investors digested fresh macro data, rising oil, and a crowded political and IPO calendar that includes California’s pivotal primary and the looming SpaceX roadshow.
Market wrap: risk-on pauses after records
Wall Street…
US equities traded just below record highs on Tuesday, June 2, 2026, as an AI-fueled tech rally ran into profit-taking and persistent geopolitical and macro uncertainty ahead of a key jobs data week. AI infrastructure names, semis, and select consumer and casino…
Eupraxia Pharmaceuticals (EPRX) and Legend Biotech (LEGN) are quietly shaping one of Wall Street’s favorite narratives in 2026: niche innovators turning complex science into potentially durable revenue streams, with just enough volatility to keep the options desks awake.
Two Different Paths,…
US stocks started June on a cautious but constructive note Monday, with the S&P 500 and Nasdaq hovering near record territory as surging oil prices and geopolitics offset another powerful bid for mega-cap tech and AI beneficiaries.
Index recap and market tone…